ScholarLens Back to search
2016•JAMA Internal MedicineOpen access

Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration

Matthew V. Abola, Vinay Prasad

Open full text 34 citations

Abstract

This study reviewed transcripts of meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration to characterize potential financial and other conflicts of interest of public speakers.

Open-access reader

About this research paper

What this paper is about

This study reviewed transcripts of meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration to characterize potential financial and other conflicts of interest of public speakers.

Why it matters

OpenAlex reports 34 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This study reviewed transcripts of meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration to characterize potential financial and other conflicts of interest of public speakers.

Key concepts: Medicine, Advisory committee, Food and drug administration, Administration (probate law), Drug, Drug administration, Drug approval, Conflict of interest

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration — Research Paper | ScholarLens